08:17 AM EDT, 10/27/2025 (MT Newswires) -- Nurix Therapeutics ( NRIX ) said Monday it has closed its underwritten offering of about 24.5 million shares priced at $10.21 per share and raising $250 million in gross proceeds.

The clinical-stage biopharmaceutical firm said the offering included participation from new and existing investors, including General Atlantic, Redmile Group, Braidwell, Deep Track Capital among others.

Nurix said it plans to use the net proceeds primarily to finance the clinical development of its drug candidates, including bexobrutideg (NX-5948) in chronic lymphocytic leukemia and for the exploration of potential autoimmune indications. The proceeds will also support research and development, working capital and other general corporate purposes, the company said.

Nurix shares were up 0.5% in premarket trading.